Literature DB >> 22593197

The changing view of high-grade serous ovarian cancer.

Els M J J Berns1, David D Bowtell.   

Abstract

The classification of epithelial ovarian cancer has been substantially revised, with an increased appreciation of the cellular origins and molecular aberrations of the different histotypes. Distinct patterns of signaling-pathway disruption are seen between and within histotypes. Large-scale genomic studies of high-grade serous cancer, the most common histotype, have identified novel molecular subtypes that are associated with distinct biology and clinical outcome. High-grade serous cancers are characterized by few driver point mutations but abundant DNA copy number aberrations. Inactivation of genes associated with DNA damage repair underlies responses to platinum and PARP inhibitors. Here we review these recent developments. ©2012 AACR

Entities:  

Mesh:

Year:  2012        PMID: 22593197     DOI: 10.1158/0008-5472.CAN-11-3911

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  67 in total

Review 1.  Lessons from postgenome-wide association studies: functional analysis of cancer predisposition loci.

Authors:  A N A Monteiro; M L Freedman
Journal:  J Intern Med       Date:  2013-11       Impact factor: 8.989

2.  Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.

Authors:  Claudia Iavarone; Ioannis K Zervantonakis; Laura M Selfors; Sangeetha Palakurthi; Joyce F Liu; Ronny Drapkin; Ursula A Matulonis; Dorothy Hallberg; Victor E Velculescu; Joel D Leverson; Deepak Sampath; Gordon B Mills; Joan S Brugge
Journal:  Mol Cancer Ther       Date:  2019-01-24       Impact factor: 6.261

3.  Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.

Authors:  Kristy K Ward; Isabelle Tancioni; Christine Lawson; Nichol L G Miller; Christine Jean; Xiao Lei Chen; Sean Uryu; Josephine Kim; David Tarin; Dwayne G Stupack; Steven C Plaxe; David D Schlaepfer
Journal:  Clin Exp Metastasis       Date:  2012-12-30       Impact factor: 5.150

Review 4.  Translating metastasis-related biomarkers to the clinic--progress and pitfalls.

Authors:  François-Clément Bidard; Jean-Yves Pierga; Jean-Charles Soria; Jean Paul Thiery
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

Review 5.  Latest research and treatment of advanced-stage epithelial ovarian cancer.

Authors:  Robert L Coleman; Bradley J Monk; Anil K Sood; Thomas J Herzog
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

6.  Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform.

Authors:  Tamal Das; Liliane Meunier; Laurent Barbe; Diane Provencher; Olivier Guenat; Thomas Gervais; Anne-Marie Mes-Masson
Journal:  Biomicrofluidics       Date:  2013-01-10       Impact factor: 2.800

7.  Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Authors:  Marcin P Iwanicki; Hsing-Yu Chen; Claudia Iavarone; Ioannis K Zervantonakis; Taru Muranen; Marián Novak; Tan A Ince; Ronny Drapkin; Joan S Brugge
Journal:  JCI Insight       Date:  2016-07-07

8.  Prognostic Significance of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) in Epithelial Ovarian Cancer.

Authors:  Gwan Hee Han; Doo Byung Chay; Sanghee Nam; Hanbyoul Cho; Joon-Yong Chung; Jae-Hoon Kim
Journal:  Cancer Genomics Proteomics       Date:  2020 May-Jun       Impact factor: 4.069

9.  Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.

Authors:  Yi Kan Wang; Ali Bashashati; Michael S Anglesio; Dawn R Cochrane; Diljot S Grewal; Gavin Ha; Andrew McPherson; Hugo M Horlings; Janine Senz; Leah M Prentice; Anthony N Karnezis; Daniel Lai; Mohamed R Aniba; Allen W Zhang; Karey Shumansky; Celia Siu; Adrian Wan; Melissa K McConechy; Hector Li-Chang; Alicia Tone; Diane Provencher; Manon de Ladurantaye; Hubert Fleury; Aikou Okamoto; Satoshi Yanagida; Nozomu Yanaihara; Misato Saito; Andrew J Mungall; Richard Moore; Marco A Marra; C Blake Gilks; Anne-Marie Mes-Masson; Jessica N McAlpine; Samuel Aparicio; David G Huntsman; Sohrab P Shah
Journal:  Nat Genet       Date:  2017-04-24       Impact factor: 38.330

10.  Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.

Authors:  Hyunah Cho; Tsz Chung Lai; Glen S Kwon
Journal:  J Control Release       Date:  2012-12-13       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.